LEADER 03843nam 2200577z- 450 001 996344234403316 005 20231214133652.0 010 $a3-8452-3103-3 035 $a(CKB)4340000000010145 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/50417 035 $a(EXLCZ)994340000000010145 100 $a20202102d2011 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aIntellectual property related generic defense strategies in the European pharmaceutical market $eimplications of the EU Commission's sector inquiry from an IP, competition law and economic perspective /$fMarc P. Philipp 210 $cNomos Verlagsgesellschaft mbH & Co. KG$d2011 215 $a1 electronic resource (92 p.) 225 1 $aMIPLC studies ;$vv. 11 300 $a"Munich Intellectual Property Law Center." 311 $a3-8329-6707-9 320 $aIncludes bibliographical references (p. 83-91). 327 $aIntroduction -- Governance framework of Europe's pharmaceutical sector -- Competitive dynamics in Europe's pharmaceutical market -- Potential future limitations for generic defense -- Implications of business model transformations -- Conclusion & managerial recommendation. 330 $aThis book discusses the implications of the 2009 EU Commission?s Pharmaceutical Sector Inquiry on originator?s opportunities to apply Intellectual Property related measures in defending against generic competition. It argues that on the one hand recent developments in EU competition law do indeed impose potential limitations on an originator?s ability to block or delay generic market entry. On the other hand, the book calls for a differentiated assessment of the rather broad allegations made by the sector inquiry. The book thereby presents and thoroughly analyzes six key issues identified by the EU Commission in the inquiry?s final report: Blocking/defensive patenting, patent thickets, patent-related disputes and litigation, follow-on innovation, authorized generic entries and patent settlement agreements as well as interventions into generic marketing authorization. The analysis aims at reducing legal uncertainty by providing a clearer picture of legal boundaries between legitimate and problematic conduct under Arts. 101 and 102 TFEU. The book also puts the sector inquiry?s findings into a forward-looking perspective by highlighting industry trends with the potential to transform traditional originator and generic business models. The author studied economics and law, has gained substantial expertise about strategy development as a consultant to the pharmaceutical industry and currently leads strategic research management at a large life sciences public research organization in Germany. 410 0$aMIPLC studies ;$vv. 11. 517 $aIntellectual Property Related Generic Defense Strategies in the European Pharmaceutical Market 606 $aDrugs$xLaw and legislation$zEuropean Union countries 606 $aDrugs$vPatents 606 $aGeneric drugs$zEuropean Union countries 606 $aAntitrust law$zEuropean Union countries 610 $aWettbewerbsrecht 610 $aHandels- und Wirtschaftsrecht 610 $aKartellrecht 615 0$aDrugs$xLaw and legislation 615 0$aDrugs 615 0$aGeneric drugs 615 0$aAntitrust law 700 $aPhilipp$b Marc P$01241970 712 02$aMunich Intellectual Property Law Center. 801 0$bBTCTA 801 1$bBTCTA 801 2$bGWL 801 2$bOHX 801 2$bYDXCP 801 2$bDLC 906 $aBOOK 912 $a996344234403316 996 $aIntellectual property related generic defense strategies in the European pharmaceutical market$92880827 997 $aUNISA